Compare TRIN & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRIN | NVAX |
|---|---|---|
| Founded | 2007 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2021 | 1995 |
| Metric | TRIN | NVAX |
|---|---|---|
| Price | $16.51 | $9.95 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 9 |
| Target Price | ★ $16.00 | $10.78 |
| AVG Volume (30 Days) | 1.3M | ★ 4.6M |
| Earning Date | 02-25-2026 | 02-26-2026 |
| Dividend Yield | ★ 12.67% | N/A |
| EPS Growth | ★ 25.79 | N/A |
| EPS | ★ 2.17 | 2.07 |
| Revenue | $268,271,000.00 | ★ $1,064,651,000.00 |
| Revenue This Year | $31.25 | $58.91 |
| Revenue Next Year | $16.06 | N/A |
| P/E Ratio | $7.43 | ★ $3.96 |
| Revenue Growth | ★ 30.76 | 20.27 |
| 52 Week Low | $12.50 | $5.01 |
| 52 Week High | $16.82 | $10.65 |
| Indicator | TRIN | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 70.03 | 76.49 |
| Support Level | $15.89 | $7.73 |
| Resistance Level | $16.34 | $8.81 |
| Average True Range (ATR) | 0.36 | 0.56 |
| MACD | 0.09 | 0.21 |
| Stochastic Oscillator | 99.26 | 99.41 |
Trinity Capital Inc is a closed-end, non-diversified management investment company. The company is engaged in providing debt, including loans and equipment financings, to growth-stage companies, including venture-backed companies and companies with institutional equity investors. Its equipment financings involve loans for general or specific use, including acquiring equipment, secured by the equipment or other assets of the portfolio company.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.